Biobeat Technologies

Petah Tikva, Israel, with a U.S. office in Boca Raton, Florida. [2, 15, 19, 27] All Israel companies → — Founded 2016 [3, 9, 17, 19]

Medical Device / Hardware Specialty-Focused AI Wearables / RPM

Cardiology Hospital Medicine Internal Medicine

Cardiology AI Wearables & Remote Monitoring (RPM)

Series B [2, 4, 8, 12, 13] — $71.8M (PitchBook) or $50M-$51M (other sources). [2, 4, 6, 8]

Website Claim this company

Products

Biobeat

Biobeat Technologies

Cardiology AI

Biobeat offers FDA-cleared vital sign measurement devices, including a chest patch and watch, for continuous, cuffless, and real-time remote patient monitoring, providing health AI and machine learning insights for proactive patient care.

See all 1 product →

About Biobeat Technologies

Biobeat Technologies is a digital health company that specializes in wearable remote patient monitoring solutions, particularly for hypertension diagnosis and management. Their core technology utilizes proprietary patented photoplethysmography (PPG) sensors integrated into non-invasive, wireless devices, such as a chest patch and a wrist monitor. These devices continuously track multiple vital signs, including cuffless blood pressure, pulse rate, respiratory rate, blood oxygen saturation, and cardiac output. [5, 18, 30]

For physicians, Biobeat’s platform offers a comprehensive approach to patient care by providing real-time, continuous data that can enhance clinical decision-making, improve patient compliance, and enable proactive interventions. [5, 7] The system aims to eliminate the discomfort and logistical challenges associated with traditional cuff-based monitoring, addressing issues like white coat syndrome and masked hypertension. [15, 16, 18] The aggregated patient health data is accessible via a secure, cloud-based patient management platform that incorporates AI-based algorithms and an automated real-time early warning score (EWS) system to provide alerts on patient health status and potential deterioration. [19, 30] This allows for more precise medication titration and personalized care plans, supporting both in-hospital and home-based care settings. [5, 7, 18]

Focus Areas

remote patient monitoring cuffless blood pressure monitoring vital signs monitoring AI-driven health insights digital health wearables hypertension management cardiac monitoring hospital-at-home solutions

Business Intelligence

Key Investors	Ally Bridge Group, OrbiMed Advisors, Elevage Medical Technologies, Kestra Medical Technologies, L Marks, BestBuy Health
Partnerships	Kestra Medical Technologies, RWJBarnabas Health, SciTech Scity, Inbound Health, Infinity Pharma, Bionex
Technology	cloud-based patient management system, proprietary non-invasive reflective photoplethysmography (PPG) sensors, AI-based algorithms, early warning score (EWS) system
FDA Clearances	7 (for various parameters including cuffless blood pressure, blood oxygen saturation, pulse rate, respiratory rate, body temperature, stroke volume, and cardiac output) cleared products (estimated)

What Physicians Need to Know

Remote Patient Monitoring (RPM)

Biobeat offers a comprehensive RPM platform with wearable wrist and chest monitors that continuously track 13 vital signs, including cuffless blood pressure, heart rate, respiratory rate, and blood oxygen saturation. This enables real-time data transmission to a cloud-based platform for continuous patient oversight in various settings, including hospital-at-home programs and decentralized clinical trials.

Cuffless Blood Pressure Monitoring

Biobeat is a pioneer in cuffless blood pressure monitoring, offering the first FDA-cleared, medical-grade solution for 24-hour ambulatory blood pressure monitoring (ABPM) using proprietary PPG sensor technology. This eliminates the discomfort and disruption of traditional cuffs, improving patient compliance and providing more accurate, continuous data for hypertension diagnosis and management.

AI-Driven Health Insights

The Biobeat platform leverages AI and machine learning on big data to provide actionable insights, predictive analytics, and automated real-time early warning scores for patient deterioration. This transforms reactive care into proactive, personalized healthcare, aiding in clinical decision-making and optimizing patient management.

Wearables & Sensors

Biobeat's core technology revolves around proprietary patented PPG (photoplethysmography) sensors integrated into lightweight, disposable chest patches and reusable wrist monitors. These devices non-invasively and continuously capture a wide range of physiological data.

Hospital-at-Home Solutions

Biobeat's technology supports hospital-at-home programs by providing continuous, hospital-grade monitoring of vital signs in a home setting. This allows for early detection of clinical deterioration, reduces hospital readmissions, and offers a flexible and scalable model for acute care outside traditional hospital walls.

Physician Tip

Biobeat's cuffless ABPM offers precise, continuous data without patient discomfort, leading to higher compliance and a more complete blood pressure profile, crucial for diagnosing masked or white coat hypertension. The AI-driven platform provides real-time alerts and insights, enabling proactive interventions and personalized treatment plans, ultimately improving patient outcomes and potentially reducing workload by automating data collection and analysis. The ability to monitor 13 vital signs continuously and wirelessly, both in-hospital and at home, supports comprehensive patient management across various clinical settings, including cardiology and hypertension centers.

Biobeat's platform is designed to transmit data to a secure cloud-based platform, and it has integrations with other digital health solutions like Datos Health's Open Care platform, allowing clinicians to manage sensor data and adjust care plans. The system also supports EMR data synchronization.

At a glance

Founded 2016 [3, 9, 17, 19]

HQ Petah Tikva, Israel, with a U.S. office in Boca Raton, Florida. [2, 15, 19, 27] · Israel

Team size Between 45 and 77 employees. [2, 4, 6, 8, 30]

CEO Arik Ben Ishay [3, 10, 11, 14]

Funding Series B [2, 4, 8, 12, 13] — $71.8M (PitchBook) or $50M-$51M (other sources). [2, 4, 6, 8]

FDA clearances 7 (for various parameters including cuffless blood pressure, blood oxygen saturation, pulse rate, respiratory rate, body temperature, stroke volume, and cardiac output) (estimated)

Products 1

Visit site

Products by Biobeat Technologies

1 product in the directory

Biobeat

Biobeat Technologies

Cardiology AI

What the Web Says

Biobeat Technologies offers non-invasive, wearable monitoring devices, such as wrist and chest monitors, that continuously track 13 vital signs using proprietary PPG sensor technology. The system is utilized for in-hospital, ambulatory, and remote patient monitoring, with applications in early deterioration detection, personalized care, and clinical research. Reviewers highlight the comfort and convenience of the devices, particularly the 24-hour skin patch for blood pressure monitoring, and the FDA approval for wrist-based measurements like blood pressure.

Overall: Mixed

Strengths

Proprietary PPG sensor technology for accurate vital sign measurement.
FDA approval for uncommon wrist-based measurements, including blood pressure.
Comfortable and non-invasive wearable devices, like the 24-hour skin patch.
Continuous, real-time tracking of 13 vital signs.
AI-based analytics for actionable insights and early warning scores.
Applicable across various clinical settings, contributing to positive patient outcomes.

Limitations

Lack of access to devices outside of a medical setting for direct purchase and use.
Absence of an explicit emergency alarm system; relies on nurses checking a dashboard for notifications.
Uncertainty regarding system behavior in cases of sudden death.
Skin patch is single-use, and information on the official homepage regarding pricing and detailed technical specifications can be lacking.
Cost of devices can be high (around $1800 per device mentioned in one review).
Some users have reported discrepancies in blood pressure readings compared to other home monitors.

Based on reviews from: Elion Health, The Medical Futurist, Reddit, PubMed, ResearchGate, Instalab

Last updated: 2026-07-27

Videos

News, demos, and interviews about Biobeat Technologies.

Loading videos...

Videos load interactively. If none appear, search YouTube for Biobeat Technologies →

View all on YouTube

Press & Coverage

Biobeat Technologies

Biobeat Secures $50 Million Series B Financing to Advance Commercialization of its Patch-worn, Cuffless 24-hour Ambulatory Blood Pressure Monitor

Biobeat Technologies announced a $50 million Series B equity financing round led by Ally Bridge Group, OrbiMed Advisors, and Elevage Medical, to expand commercialization of its FDA-cleared, patch-worn, cuffless 24-hour ambulatory blood pressure monitoring (ABPM) system in the United States.

2025-12

MedTech Dive

Biobeat raises $50M to commercialize cuffless blood pressure monitor | MedTech Dive

Biobeat Technologies secured $50 million in Series B funding to commercialize its cuffless blood pressure monitor in the U.S., aiming to establish it as a preferred option for 24-hour blood pressure monitoring.

2026-01

Fierce Biotech

Biobeat Technologies drums up $50M for its cuffless blood pressure monitor | Fierce Biotech

Biobeat Technologies raised $50 million in a Series B round to boost the commercialization of its FDA-cleared, 24-hour patch-worn blood pressure sensor, which aims to replace traditional cuff-based monitoring for hypertension diagnosis and treatment.

2026-01

Biobeat Technologies

Biobeat Announces Strategic partnership with Kestra Medical Technologies

Biobeat announced a strategic collaboration with Kestra Medical Technologies, including a $5 million equity investment, to integrate Biobeat's FDA-cleared cuffless ABPM technology into Kestra's product portfolio for wearable defibrillator patients.

2026-01

Biobeat Technologies

Clinical Validation That Matters: Biobeat's Latest White Paper

Biobeat released a white paper detailing the rigorous clinical validation of its FDA-cleared, medical-grade, cuffless PPG-based chest patch, highlighting a Mayo Clinic study that demonstrated strong correlation with invasive arterial blood pressure monitoring.

2026-06

PubMed (Digit Health)

Biobeat monitor utilization in various healthcare settings: A systematic review - PubMed

A systematic review published in Digital Health in February 2025 concluded that Biobeat's non-invasive wearable devices, including the wrist monitor and chest patch, have been effectively utilized across various clinical settings, consistently contributing to positive patient outcomes.

2025-02

Biobeat Technologies

Biobeat's Latest Research Published in JACC Journals: Advances

Biobeat's research, published in JACC Journals: Advances, validated the accuracy of its noninvasive photoplethysmography (PPG) device for cardiac flow measurements, showing a high correlation with invasive pulmonary artery catheter measurements in heart failure patients.

2025-08

Biobeat Technologies

Biobeat Launches Integrated Patient Diary to Unlock Deeper Insights for Hypertension Diagnosis and Management

Biobeat launched its Patient Diary feature within its FDA-cleared, cuffless 24/7 hypertension monitoring platform, allowing patients to log medications, exercise, meals, sleep, mood, and stress for more personalized and efficient hypertension management.

2025-11

Frequently Asked Questions

What specific vital signs and health parameters can Biobeat's remote patient monitoring (RPM) devices track, and how does this benefit hypertension and cardiac care?

Biobeat's wearable devices, including a chest patch and wrist monitor, continuously track 13 vital signs such as cuffless blood pressure, pulse rate, respiratory rate, blood oxygen saturation, stroke volume, and cardiac output. This comprehensive, real-time data helps clinicians diagnose and manage hypertension more effectively, personalize treatment plans, and monitor patient response to therapy, ultimately supporting improved clinical outcomes and proactive interventions in both in-hospital and home-based care.

How accurate and clinically validated is Biobeat's cuffless blood pressure monitoring technology?

Biobeat's cuffless blood pressure monitoring technology has received FDA clearance and CE certification, making it the first of its kind to be FDA-cleared for cuffless blood pressure monitoring using only PPG. Clinical studies have demonstrated its accuracy and reliability, showing strong correlation and minimal bias when compared to traditional cuff-based devices and even invasive arterial blood pressure monitoring. This allows for objective, continuous, and comfortable blood pressure measurement, reducing issues like 'white coat syndrome' and improving patient compliance.

What are Biobeat's solutions for hospital-at-home programs and how do they integrate with existing healthcare systems?

Biobeat's technology is designed to support hospital-at-home programs by providing continuous, medical-grade monitoring solutions that enhance clinical decision-making and enable proactive interventions. Their devices integrate with cloud-based monitoring and analytics platforms, allowing medical staff to view real-time patient data and receive alerts. Biobeat also partners with platforms like Current Health (Best Buy Health) and Datos Health to scale care-at-home capabilities and integrate continuous monitoring into advanced care solutions.

What kind of AI-driven health insights does Biobeat's platform provide to physicians and healthcare administrators?

Biobeat's platform leverages AI and machine learning to analyze continuous vital sign data, generating actionable insights for healthcare providers. This includes early warning scores (EWS) that can predict patient deterioration significantly earlier than traditional methods, allowing for timely interventions. The AI also helps in identifying trends, correlating symptoms with vital signs, and personalizing treatment decisions for chronic conditions like hypertension.

What is Biobeat's regulatory compliance status, data security measures, and overall company stability?

Biobeat's devices are FDA-cleared and CE-certified, and the company has achieved MDSAP certification, demonstrating compliance with international medical device regulations. They prioritize data privacy and security, with their cloud-based platform being HIPAA and GDPR compliant. Biobeat is a Series B company, founded in 2014, that has raised $51 million in funding from investors like Ally Bridge Group, OrbiMed Advisors, and Elevage Medical, indicating strong financial backing and stability for commercial expansion.

Related Companies

Suggest an Edit →